Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Other Non-Current Liabilities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $12000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 53.27% year-over-year to $12000.0, compared with a TTM value of $12000.0 through Sep 2025, down 53.27%, and an annual FY2024 reading of $21680.0, changed 0.0% over the prior year.
  • Other Non-Current Liabilities was $12000.0 for Q3 2025 at Abvc Biopharma, down from $41680.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $41680.0 in Q2 2025 and bottomed at $5680.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 5 years is $15902.1, with a median of $12000.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Liabilities tumbled 55.9% in 2023, then skyrocketed 387.32% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $10580.0 in 2021, then decreased by 24.57% to $7980.0 in 2022, then skyrocketed by 171.68% to $21680.0 in 2023, then changed by 0.0% to $21680.0 in 2024, then tumbled by 44.65% to $12000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ABVC at $12000.0 in Q3 2025, $41680.0 in Q2 2025, and $21680.0 in Q1 2025.